UK Courts Uphold Lilly Alimta Patents

Jul 10, 2017


The London-based Supreme Court found that Actavis products infringe Eli Lilly patents for its third best-selling drug, Alimta.

The court ruled that Activis generic pemetrexed products violated Lilly’s patent for pemetrexed disodium-based cancer treatment in the UK, France, Italy and Spain prior to June 2021.

Actavis, now owned by Teva, launched its pemetrexed Armisarte in June 2015.

Read the Bloomberg coverage

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments